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Integrated and Single Use Continuous Manufacturing 
 
Atul Mohindra, Lonza Biologics 
Atul.mohindra@lonza.com 
 
Continuous processing for biopharmaceutical production is attracting considerable interest within the 
industry.  The concept of continuous processing is not new and the value of continuous manufacturing 
has been well documented for decades across the steel, chemicals and food industries.  Despite the 
vast differences between product types, the advantages of continuous over batch production remain 
consistent and include steady state operation, high volumetric productivity, streamlined process flow 
and reduced capital costs. 
 
Over the past decade, significant investments have already been made with continuous bio-
manufacturing development.  The need for the biopharmaceutical industry to follow suit is being 
influenced by a number of business drivers including:  
 
 accelerated development times for continuously operated steps 
 reducing overall costs 
 maintaining stringent quality/regulatory requirements  
 flexibility to match changing product demands 
 
At present, contract manufacturing organisations often need to flexibly accommodate large-, mid- and 
small-volume drugs (e.g., therapeutic proteins, niche or orphan drugs), preferably within the same 
manufacturing facilities. Furthermore, the ability to rapidly adjust production capacity to accommodate 
fluctuating and/or mis-forecasted demands is also needed.  In order to ensure that Lonza maintains the 
required level of flexibility, our vision is to put in place even more flexible production capabilities utilising 
both continuous and batch processes whilst lowering the risks associated during process execution and 
process transfers. 
 
Over the past decade, we have focussed on developing simplified, efficient and robust mammalian cell 
culture/purification platform processes.  More recent activities have focussed on taking advantage of 
new and converging single use technologies as well as ensuring that we use state of the art analytical 
tools at the right time and at the right place in our processes.  We are now looking to move one step 
further by integrating the single use unit operations which will allow for processes to be operated in a 
continuous mode. 
 
This poster will outline Lonza’s approach to establish continuous flexible manufacturing facilities 
using single use technologies. 
